Genomic characterization of long-term responders to olaparib.
Stéphanie Lheureux(Princess Margaret Cancer Centre), Amit M. Oza(Ontario Institute for Cancer Research), Zhongwu Lai(AstraZeneca (United States)), David D.L. Bowtell(The University of Melbourne), Sarah Runswick(Allgemeine Gewerbeschule Basel), Kirsten M. Timms(Myriad (Germany)), J. Carl Barrett(Imperial College Healthcare NHS Trust), Ursula A. Matulonis(Dana-Farber Cancer Institute), Mark J. O’Connor(AstraZeneca (United Kingdom)), Jerry S. Lanchbury(Myriad Genetics), Tony Panzarella(Princess Margaret Cancer Centre), Jonathan A. Ledermann(London Cancer), Clare L. Scott(Walter and Eliza Hall Institute of Medical Research), Brian Dougherty(AstraZeneca (United States)), Darren Hodgson(AstraZeneca (United Kingdom)), Tony Weishiu Ho(Wilmington University), Stanley B. Kaye(Royal Marsden Hospital), Elise C. Kohn(National Cancer Institute), Jane Robertson(Cancer Research UK), Charlie Gourley(Edinburgh Cancer Research)
Cited by 3
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k